Image

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Recruiting
18 years of age
Both
Phase 3

Powered by AI

Overview

The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or gastroesophageal junction adenocarcinoma. PD-1+CRT cohort: A total of 216 patients will receive 6 weeks of PD-1 inhibitors and chemotherapy, then receive concurrent chemoradiotherapy, followed by 6 weeks of PD-1 inhibitors and chemotherapy, finally receive maintenance treatment of PD-1 inhibitors until (maximum 1year after radiotherapy). CT cohort: A total of 217 patients will receive 6 months of chemotherapy. The disease-free survival(DFS), overall survival(OS) and adverse effects will be analyzed.

Eligibility

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
  • Patients with expected survival time more than 6 months
  • Patients after standard D2/R0 resection
  • Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ
  • Positive lymph nodes more than 7, stage pN3
  • Patients without distant metastasis (M0) or M1 with abdominal exfoliated cell detection positive (CY1P0)
  • Patients' physical condition and visceral function allows following adjuvant therapy, including chemotherapy, chemoradiotherapy and PD-1 inhibitor therapy.
  • Patients' blood routine and biochemical indicators should meet the following standard: Hb≥90g/L, ANC≥1.510^9/L, PLT≥10010^9/L, ALT & AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine<1 UNL.
  • Patients who are willing to obey regimens during the study.
  • Written informed consent is acquired before random entry, and patients should know that he/she has the right to quit, and following treatment won't be affected.
  • Patients are willing to provide samples of blood and tissue.

Exclusion Criteria:

  • Patients with gross peritoneal metastasis (CY1P0 excluded) or distant metastasis.
  • Patients who has received any anti-tumor therapy before surgery.
  • Patients who had received radiotherapy for abdominal organs including stomach, liver, kidney, etc.
  • Patients who had active systematic autoimmune diseases which need systematic treatment within 2 years before first medication in the study, substitutive therapy (such as thyroxine, insulin, etc) excluded.
  • Patients diagnosed with immunodeficiency, or was receiving systematic glucocorticoid treatment or other immunosuppressive therapy within 7 days before medication, physiological dose of glucocorticoid is allowed (≤10 mg/d prednison or equivalent medication)
  • Patients who have known severe allergic reaction (≥level 3) to anti-PD-1 monoclonal antibody, 5-FU, Oxaliplatin or any auxiliary material.
  • Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.
  • Patient with severe vital organ failure.
  • Pregnant or lactation period
  • Patient with known mental illness or drug abuse that may influence compliance.
  • Patient with known HIV infection, or active tuberculosis.
  • Untreated active hepatitis B
  • Patient with active HCV infection
  • Uncontrolled complications
  • Other situations that might disturb study results and compliance.

Study details

Gastric Cancer

NCT04997837

Fudan University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.